Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

10.3%

8 terminated/withdrawn out of 78 trials

Success Rate

81.8%

-4.8% vs industry average

Late-Stage Pipeline

13%

10 trials in Phase 3/4

Results Transparency

11%

4 of 36 completed trials have results

Key Signals

17 recruiting4 with results8 terminated

Enrollment reporting

Analytics

Phase 2

44(65.7%)

Phase 3

8(11.9%)

Phase 1

5(7.5%)

Phase 2/3

3(4.5%)

Phase 1/2

3(4.5%)

N/A

2(3.0%)

Phase 4

2(3.0%)

67Total

Phase 2(44)

Phase 3(8)

Phase 1(5)

Phase 2/3(3)

+3 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (78)

Showing 20 of 78 trials

NCT05460000Phase 2Recruiting

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

Role: collaborator

NCT06440993Phase 2Recruiting

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic Cholangiocarcinoma

Role: lead

NCT07110038Phase 2Recruiting

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

Role: lead

NCT04495088Phase 3Terminated

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

Role: collaborator

NCT07844057Phase 2Not Yet Recruiting

First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma

Role: collaborator

NCT07260175Phase 2Recruiting

Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

Role: lead

NCT05504720Phase 2Completed

Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma

Role: lead

NCT05713838Phase 2Active Not Recruiting

Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

Role: lead

NCT04375605Phase 3Completed

Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ

Role: collaborator

NCT03081143Phase 2/3Completed

Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy

Role: lead

NCT07176312Phase 2Recruiting

Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

Role: lead

NCT04318938Phase 2Completed

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Role: lead

NCT04522544Phase 2Active Not Recruiting

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Role: lead

NCT05825625Phase 2Active Not Recruiting

NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

Role: lead

NCT07255664Phase 1/2Recruiting

A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC

Role: collaborator

NCT07387198Phase 2Recruiting

Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab

Role: lead

NCT04879368Phase 3Completed

RegoNivo vs Standard of Care Chemotherapy in AGOC

Role: collaborator

NCT06731803Phase 1/2Active Not Recruiting

Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma

Role: lead

NCT07542678Phase 2Not Yet Recruiting

Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation Concept

Role: lead

NCT05393674Phase 2Completed

Fedratinib in Combination With Nivolumab

Role: lead